Patents for treatments associated with neurodegenerative diseases, valid through 2025.

Hyderabad-based biopharmaceutical company Suven Life Sciences (Suven) said it has secured three product patents, one each from Canada, China and India. The patents correspond to the new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases. These patents are valid through 2025.

The patents include the class of selective 5-HT compounds discovered by Suven, which are being developed as therapeutic agents. These are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.

With these new patents, Suven has a total of 14 granted patents from Canada, 12 patents from China and 17 from India.

“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need and with huge market potential globally” chief executive officer, Venkat Jasti, said in a press release on Friday.

source: http://www.business-standard.com / Business Standard / Home> Companies> News / by Prashanth Chintala / Hyderabad – January 31st, 2014